Risk assessment for Deep venous thromboembolism in children admitted in Pediatric intensive care unit and role of prophylactic Enoxaparin sodium

Risk assessment for hospital-acquired venous thromboembolism in critically ill children admitted in alexandria university pediatric intensive care unit

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202602877136281

Enrollment

100

Registered

2026-02-04

Start date

2023-06-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paediatrics

Interventions

Giving Enoxparin sodium when there is DVT

Prophylactic Enoxparin sodium

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Recent central venous catheter placement within 30 days prior or within 24 hour of ICU admission. - Length of hospital stay greater than or equal 3 days prior to ICU admission. - History of DVT (VTE) or pulmonary embolism in the past. - Immobility. - Obesity. - Family history of coagulopathy. - Nephrotic syndrome. - Infection including bacteremia sepsis infections of the gastrointestinal tract meningitis pneumonia and upper respiratory tract infections.

Exclusion criteria

Exclusion criteria: • Recent cardiac surgery. • Patients with bleeding disorders congenital or acquired. • Patients known to have thrombophilic diseases. • Contraindications to Enoxaparin Use in Critically Ill Pediatric Patients.

Design outcomes

Primary

Measure	Time frame
•Define the value of thromboprophylaxis treatment in high risk patients in preventing thromboembolic manifestations.	—

Secondary

Measure	Time frame
• Efficacy and safety of pharmacological thromboprophylaxis in critically ill patient in prevention of HA-VTE. • Effect of thromboprophylaxis treatment on length of stay in PICU • Effect of thromboprophylaxis treatment prognosis/mortality. • Relation between duration of therapy and VTE occurrence.	—

Countries

Egypt

Contacts

Public ContactDr Manal Abdelmalak

Prof

amrelmahalawy466@gmail.com01283024875

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026